USFDA denies Sun Pharma Advanced Research’s appeal of NDA for Taclantis
The company will review FDA's response and decide on appropriate next steps soon.
The company will review FDA's response and decide on appropriate next steps soon.
The company posted net loss of Rs. 55.51 crores for the period ended December 31, 2019.
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
Performance driven by growth portfolio momentum, pipeline advancements, and strategic business development
Dr. Jindal reflects on bridging accessibility gaps between urban and rural regions, the ethical and emotional aspects of family building, and how initiatives like adoption facilitation centers align with his lifelong mission to help couples realize the dream of parenthood
Cobenfy generated $43 million in third-quarter sales, up from $35 million in the second quarter
Vitiligo, affecting over 90 per cent of patients in its non-segmental form, is characterized by symmetrical white patches on both sides of the body
The quarter included three IPOs worth US$ 428 million and one Qualified Institutional Placement (QIP) worth US$ 88 million
Quest Diagnostics’ blood-based test panels demonstrate confirmatory accuracy, potentially reducing the need for PET imaging
Subscribe To Our Newsletter & Stay Updated